Shares of Sarepta jumped 22% to $19.65 in after-hours trading. SRPT has a 1-year high of $41.97 and a 1-year low of $8. The stock’s 50-day moving average is $17.45 and its 200-day moving average is $21.93.
On the ratings front, Sarepta has been the subject of a number of recent research reports. In a report released today, Jefferies Co. analyst Gena Wang reiterated a Sell rating on SRPT, with a price target of $7, which reflects a potential downside of -56.4% from last closing price. Separately, on June 2, Piper Jaffray’s Edward Tenthoff reiterated a Sell rating on the stock and has a price target of $6.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Gena Wang and Edward Tenthoff have a total average return of -8.1% and -0.7% respectively. Wang has a success rate of 46% and is ranked #3490 out of 3894 analysts, while Tenthoff has a success rate of 39% and is ranked #2824.
Overall, 5 research analysts have rated the stock with a Sell rating, 4 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $27.60 which is 72.0% above where the stock opened today.
Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. The company is primarily focused on rapidly advancing the development of its potentially disease modifying duchenne muscular dystrophy drug candidates.